Months 1-2: Body Composition Starts Shifting
With IGF-1 now sustained at elevated levels, the downstream anabolic and metabolic effects begin to manifest.
Fat-free mass increases. Svensson et al. (1998) demonstrated that 2 months of MK-677 at 25 mg daily in obese subjects increased GH secretion, fat-free mass, and basal metabolic rate (PMID 9467542). The fat-free mass change at this stage includes both genuine lean tissue accretion and GH-mediated intramuscular water — separating the two requires DEXA or similar imaging.
Muscle fullness. Users commonly report looking "fuller" by weeks 6-8. This is a combination of increased glycogen storage, intramuscular water from GH, and early protein synthesis effects. It is visible in the mirror before it shows on a scale.
Anti-catabolic protection. Murphy et al. (1998) showed MK-677 reversed diet-induced nitrogen wasting — meaning it preserved muscle protein even during caloric restriction (PMID 9467534). For users running MK-677 during a cut, this is the phase where trial data describe more lean mass retained than without it.
Appetite stabilization. The intense hunger from weeks 1-2 typically mellows by month 2 as ghrelin receptors partially adapt. It does not disappear entirely — MK-677 is a ghrelin mimetic by design — but most users find it manageable.
Bone turnover markers increase. Svensson et al. (1998) measured a 23% increase in bone formation markers (C-terminal propeptide of type I procollagen) and 28% increase in procollagen III peptide after just 2 weeks, with effects continuing through month 2 (PMID 9661080). This is not felt directly, but it signals active bone remodeling.
Insulin sensitivity. Fasting glucose may tick upward. This is a documented effect of sustained GH elevation and is dose-dependent and reversible upon discontinuation. Pre-diabetic markers are worth monitoring.
Months 3-6: Long-Term Gains and Sustained IGF-1
This is where MK-677's long-duration clinical data becomes uniquely valuable. Most GH peptide trials last 4-8 weeks. MK-677 has 2-year data.
Sustained IGF-1 elevation without desensitization. The Nass et al. (2008) 2-year RCT confirmed that 25 mg daily MK-677 maintained elevated GH and IGF-1 throughout the study period. No significant desensitization occurred at the hormonal level (PMID 18981485).
Progressive fat-free mass gains. The Nass study showed MK-677 recipients continued gaining fat-free mass over 12 months, while the placebo group lost fat-free mass. However — and this is an important caveat — these gains did not translate to measurable strength or functional improvements in the elderly study population.
Bone density. Bone remodeling initiated in months 1-2 begins translating to measurable density changes at 6+ months. Murphy et al. (2001) showed MK-677 combined with alendronate increased femoral neck BMD by 4.2% versus 2.5% with alendronate alone in postmenopausal women (PMID 11238495). Standalone bone density effects from MK-677 require extended use.
Side effect profile stabilizes. Water retention typically normalizes by month 2-3. Appetite remains elevated but manageable. Sleep benefits persist. The main ongoing concern is insulin sensitivity — worth monitoring with periodic fasting glucose checks.
Days 1-5
Appetite increase, sleep improvement
Copinschi 1997 (polysomnography)
Weeks 2-4
Water retention, IGF-1 stabilization
Chapman 1996 (IGF-1 kinetics)
Months 1-2
Fat-free mass increase, metabolic rate rise
Svensson 1998 (body composition)
Months 3-6
Sustained lean mass gains, bone turnover
Nass 2008 (2-year RCT)
Months 6-12+
Bone density changes, long-term recomposition
Nass 2008, Murphy 2001
Factors That Affect Results
MK-677 produces elevated GH and IGF-1. What is done with that signal determines the outcomes.
Dose. Clinical trials used 25 mg daily. Community protocols range from 10-25 mg. Lower doses (10 mg) produce measurable GH elevation but with diminished downstream effects. Most users settle at 20-25 mg for optimal results. See the MK-677 Dosing Guide for full protocols.
Timing. Bedtime dosing aligns with natural nocturnal GH pulses and mitigates daytime appetite. This is the standard protocol for a reason — it works with the body's biology rather than against it.
Training stimulus. The Nass study's lack of strength improvements in elderly subjects likely reflects the absence of a training stimulus. GH and IGF-1 enhance protein synthesis, but without resistance training to create the adaptive signal, the anabolic potential is underutilized. Younger, trained individuals combining MK-677 with structured resistance training are more likely to see functional muscle gains.
Diet. MK-677's appetite stimulation makes caloric surplus easy — potentially too easy. For body recomposition, tracking intake is important. The anti-catabolic data from Murphy et al. suggests MK-677 is particularly useful during caloric deficit for muscle preservation.
Age. Older adults with lower baseline GH/IGF-1 may see more dramatic hormonal changes (Chapman et al. showed IGF-1 nearly doubling in elderly subjects). Younger users with already-adequate GH levels may see more modest relative improvements.
Sleep quality. GH release peaks during deep sleep. MK-677 improves sleep architecture, creating a positive feedback loop — but poor sleep hygiene, alcohol, and late-night screens can blunt this effect.
Results by Use Case
Muscle Growth and Body Recomposition
Weeks 1-3: Increased appetite, fuller muscles (water/glycogen), no real tissue change
Weeks 4-8: Early lean mass gains, improved recovery between sessions
Months 2-6: Progressive body composition improvement, best results with consistent resistance training
Key factor: Training stimulus is essential — MK-677 provides the hormonal environment, but the adaptive signal comes from training
Recovery and Injury Support
Week 1: Improved sleep quality accelerates overnight recovery
Weeks 2-4: Reduced DOMS, faster recovery between training sessions
Months 1-3: Sustained GH/IGF-1 supports tissue repair processes
Key factor: MK-677 supports recovery indirectly through GH elevation — it is not a targeted healing peptide like BPC-157
Anti-Aging and GH Restoration
Week 1: Sleep improvement (often the most immediately appreciated effect)
Weeks 2-4: IGF-1 restored to young-adult range (documented in Chapman 1996)
Months 3-12: Progressive improvements in skin quality, recovery capacity, body composition
Key factor: Longest use-case timeline — benefits accumulate over months, not weeks
Muscle Preservation During Cutting
Week 1: Anti-catabolic protection begins with first GH elevation
Weeks 2-8: Nitrogen balance preserved despite caloric deficit (Murphy 1998 data)
Key factor: Appetite stimulation works against the goal here — community protocols emphasize bedtime dosing and consistent calorie tracking
When to Adjust the Protocol
Signs it is working (weeks 2-4):
Increased appetite (confirms ghrelin receptor activation)
Deeper sleep, easier time falling asleep
Mild water retention (confirms GH elevation)
Improved recovery between training sessions
Signs that may warrant an adjustment:
Excessive water retention or edema lasting beyond week 4 — consider reducing dose to 10-15 mg
Persistent lethargy beyond week 3 — check blood glucose, consider morning dosing
No appetite change after 2 weeks — verify product quality and dosing accuracy
Joint pain or carpal tunnel symptoms — typically dose-dependent, reduce and reassess
When to stop:
Fasting glucose consistently elevated above baseline range
Persistent edema not responding to dose reduction
Any unusual symptoms — discontinue and consult a healthcare provider
MK-677 clears the system within days due to its approximately 24-hour half-life. Effects reverse within 2-4 weeks of discontinuation, with GH and IGF-1 returning to baseline (confirmed in the Nass 2-year study).